Skip to Main Content
Table 3.

Three-way sensitivity analysis assuming similar grade distribution between finasteride and placebo arms

Relative risk reduction (%)Cost of finasteride (U.S. $/mo)Lifetime prevalence (men diagnosed after age of 50 yr)
151.0% ($)30.0% ($)40.0% ($)50.0% ($)
25 15 114,516 65,071 48,749 35,941 
 30 261,267 143,820 104,844 73,924 
 62 578,411 314,006 226,072 156,010 
50 15 51,433 26,806 18,733 12,481 
 30 124,344 65,709 46,307 30,999 
 62 281,911 149,783 105,897 71,019 
80 15 27,696 12,304 7,260 3,357 
 30 72,908 36,253 24,120 14,544 
 62 170,617 88,008 60,555 38,721 
Relative risk reduction (%)Cost of finasteride (U.S. $/mo)Lifetime prevalence (men diagnosed after age of 50 yr)
151.0% ($)30.0% ($)40.0% ($)50.0% ($)
25 15 114,516 65,071 48,749 35,941 
 30 261,267 143,820 104,844 73,924 
 62 578,411 314,006 226,072 156,010 
50 15 51,433 26,806 18,733 12,481 
 30 124,344 65,709 46,307 30,999 
 62 281,911 149,783 105,897 71,019 
80 15 27,696 12,304 7,260 3,357 
 30 72,908 36,253 24,120 14,544 
 62 170,617 88,008 60,555 38,721 

NOTE: Results are cost per life year saved.

Close Modal

or Create an Account

Close Modal
Close Modal